Legend Biotech Corporation (LEGN) ニュース

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 millionMHRA and Health...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

SOMERSET, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA

First analysis of CARTITUDE-2 Cohort D study investigating CARVYKTI® in multiple myeloma with suboptimal response after front-line ASCT featured...

Legend Biotech to Participate in the Jefferies Global Healthcare Conference

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

First disclosure from Cohort D of the Phase 2 CARTITUDE-2 study investigating CARVYKTI® in patients who had suboptimal response to frontline...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $157 million EC and US FDA approved CARVYKTI® label expansion...